Logo

Alnylam Licenses RNAi Patent Family to Qiagen

Sep 21, 2005

NEW YORK, Sept. 21 (GenomeWeb News) - Qiagen has licensed a number of RNA interference patents from Alnylam Pharmaceuticals, Alnylam said today.

 

Under the non-exclusive license, Qiagen will be allowed to provide research products and services using RNAi under the Kreutzer-Limmer patent family, which covers small interfering RNAs and their use to mediate RNAi in mammalian cells.

 

Qiagen already offers siRNA libraries and high-throughput siRNA synthesis technology.

Breaking News
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.